Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Apr 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict outcomes for patients who have both coronary heart disease (CHD) and chronic kidney disease (CKD). These conditions can significantly impact health and are often linked, but current methods to manage them haven't been very effective. Researchers have found that certain substances in the blood, called lipid metabolites, may be higher in patients with these diseases, which could help explain why some patients do worse than others. The goal of the trial is to create a tool that helps doctors identify patients at greater risk of complications and to improve treatment strategies to enhance patient care.

To participate in the trial, individuals must be between 18 and 80 years old and have a diagnosis of CHD confirmed by a medical procedure called coronary angiography. They also need to have a clear understanding of their kidney function, specifically if they have CKD. Participants will undergo assessments that include blood tests to measure lipid metabolites, and their health will be closely monitored throughout the study. This research aims to provide important insights that could lead to better management of patients with both CHD and CKD, ultimately improving their health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-80 years old;
• • 2. Diagnosed with CHD during hospitalization through coronary angiography, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NST-ACS), stable angina pectoris;
• • 3. Patients with clarified renal function status.;
• • CKD is defined as meeting one of the following criteria, with a duration of more than 3 months: eGFR \< 60 ml/min/1.73 m² or eGFR ≥ 60 ml/min/1.73 m² and urinary albumin-to-creatinine ratio (uACR) ≥ 30 mg/g;
• Exclusion Criteria:
• • 1. Pregnancy or lactation;
• • 2. Severe valve disease or severe mechanical complications requiring surgical intervention;
• • 3. Severe psychiatric illness or other reasons that impede follow-up compliance;
• • 4. Severe hematologic disorders or end-stage malignant tumors;
• • 5. Having undergone kidney transplantation or long-term maintenance dialysis;
• • 6. Severe liver disease (Child-Pugh class C);
• • 7. Received acute renal failure dialysis treatment within 12 weeks prior to screening for enrollment;
• • 8. Severe chronic lung disease requiring long-term mechanical ventilation support or awaiting lung transplantation;
• • 9. Life expectancy less than 1 year.